No Fetal Risks with First Trimester NSAID Use

Save

PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk. 

Where are we with Biomarkers in Rheumatoid Arthritis?

Save

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

Redefining axial spondyloarthritis

Save

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

JAMA Review on Low Back Pain

Save

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE. While the primary audience is generalists, the review carries important implications for rheumatologists who regularly encounter patients with back pain in the context of inflammatory arthritis, axial spondyloarthritis, and other systemic diseases.

Do You Zoster Vaccinate? (6.19.2026)

Save

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

CAR-T Cell Therapies at EULAR 2026

Save

In an oral abstract presentation on Wednesday 3^rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullin

EULAR26 Insights into Gout and Obesity

Save

New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied to higher diabetes and cardiovascular risk.

A Disease Seeking Its Identity: Peripheral SpA, PsA, and the SPARTACUS Evidence

Save

For years, peripheral spondyloarthritis has been managed with a cautious, stepwise approach: start with NSAIDs, escalate to conventional synthetic DMARDs, and only reach for biologics when everything else fails. The SPARTACUS trial, presented at EULAR 2026 in London, challenges that paradigm head-on. The results make a compelling case for rethinking when, not just whether, to deploy TNF inhibitors.

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

Save

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Late-Breaking Studies at EULAR 2026

Save

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis

Save

On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12 recommendations.

From Cytokine Endotypes to Clinical Reality in Still’s Disease

Save

Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.

Increased VTE Risk with Baricitinib

Save

The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.

Imaging in SpA: are we seeing a clearer picture?

Save

As EULAR2026 comes to a close, practical learnings take precedence as clinicians head back to their clinics. Among them, the 2026 EULAR Update on Imaging Recommendations in SpA stands out.

From BiTE to TriTE: Progress of T-cell Engagers in RMDs

Save

The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).